Rezolute (RZLT) POS AM 13 Oct 15 Prospectus update (post-effective amendment) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Jun. 30, 2015
Document Information [Line Items]
Document Type	POS AM
Amendment Flag	false
Document Period End Date	Jun. 30, 2015
Entity Registrant Name	AntriaBio, Inc.
Entity Central Index Key	1,509,261
Entity Filer Category	Smaller Reporting Company
Trading Symbol	ANTB

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Current assets
Cash	$ 5,278,706	$ 5,934,534
Restricted cash	450,167	0
Inventory	67,218	289,600
Other current assets	320,293	83,425
Total current assets	6,116,384	6,307,559
Non-current assets
Fixed assets, net	4,524,912	337,932
Intangible assets, net	58,906	9,161
Deposit	563,000	750,000
Total non-current assets	5,146,818	1,097,093
Total Assets	11,263,202	7,404,652
Current liabilities:
Accounts payable and accrued expenses	1,408,399	460,311
Accounts payable and accrued expenses - related party	0	397,055
Convertible notes payable	60,000	60,000
Deferred lease liability, current portion	98,671	0
Lease payable, current portion	93,852	0
Interest payable	13,079	11,079
Warrant derivative liability	31,777	35,595
Total current liabilities	1,705,778	964,040
Non-current liabilities:
Deferred lease liability, less current portion	480,490	33,881
Lease payable, less current portion	23,127	0
Total non-current liabilities	503,617	33,881
Total Liabilities	$ 2,209,395	$ 997,921
Commitments and Contingencies (Note 12)
Stockholders' equity:
Preferred stock, $0.001 par value; 20,000,000 shares authorized; none issued and outstanding	$ 0	$ 0
Common stock, $0.001 par value, 200,000,000 shares authorized; 24,338,219 and 18,091,792 shares issued and outstanding, June 30, 2015 and 2014, respectively	24,341	18,092
Additional paid-in capital	38,138,754	24,135,563
Accumulated deficit	(29,109,288)	(17,746,924)
Total stockholders' equity	9,053,807	6,406,731
Total Liabilities and Stockholders' Equity	$ 11,263,202	$ 7,404,652

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Jun. 30, 2014
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	20,000,000	20,000,000
Preferred stock, issued	0	0
Preferred stock, outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	24,338,219	18,091,792
Common stock, shares outstanding	24,338,219	18,091,792

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Research and development
Compensation and benefits	$ 2,068,236	$ 0
Consultants and outside costs	742,229	34,317
Material manufacturing costs	1,355,882	0
Facilities and other costs	534,862	0
Research and development	4,701,209	34,317
General and Administrative
Consulting fees	349,633	579,817
Compensation and benefits	3,778,791	2,260,598
Professional fees	526,257	724,385
Investor relations	523,345	661,914
General and administrative	818,647	915,002
General and Administrative	5,996,673	5,141,716
Total operating expenses	10,697,882	5,176,033
Loss from operations	(10,697,882)	(5,176,033)
Other income (expense)
Interest income	4,970	12,180
Interest expense	(6,729)	(4,230,112)
Derivative losses	(662,723)	(336,489)
Total other income (expense)	(664,482)	(4,554,421)
Net loss	$ (11,362,364)	$ (9,730,454)
Net loss per common share - basic and diluted	$ (0.54)	$ (1.04)
Weighted average number of common shares outstanding - basic and diluted	20,950,191	9,384,662

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at Jun. 30, 2013	$ (4,162,212)	$ 6,667	$ 3,847,591	$ (8,016,470)
Balance (in shares) at Jun. 30, 2013		6,666,667
Stock-based compensation	1,081,792	$ 0	1,081,792	0
Beneficial conversion feature	2,922,938	0	2,922,938	0
Fair value of warrants for financing and conversion	6,476,606	0	6,476,606	0
Fair value of warrants issued	690,187	0	690,187	0
Issuance of common stock	3,483,408	$ 5,725	3,477,683	0
Issuance of common stock (in shares)		5,725,327
Issuance of common stock for note conversions	4,964,879	$ 5,298	4,959,581	0
Issuance of common stock for note conversions (in shares)		5,297,964
Issuance of common stock as repayment of related party balance	275,000	$ 176	274,824	0
Issuance of common stock as repayment of related party balance (in shares)		176,283
Cashless exercise of warrants	0	$ 101	(101)	0
Cashless exercise of warrants (in shares)		100,550
Issuance of common stock for services	404,587	$ 125	404,462	0
Issuance of common stock for services (in shares)		125,001
Net loss	(9,730,454)	$ 0	0	(9,730,454)
Balance at Jun. 30, 2014	6,406,731	$ 18,092	24,135,563	(17,746,924)
Balance (in shares) at Jun. 30, 2014		18,091,792
Stock-based compensation	2,846,828	$ 0	2,846,828	0
Fair value of warrants issued	6,026,070	0	6,026,070	0
Issuance of common stock	$ 4,768,123	$ 6,042	4,762,081	0
Issuance of common stock (in shares)	166,668	6,040,921
Issuance of common stock for services	$ 368,419	$ 207	368,212	0
Issuance of common stock for services (in shares)		205,506
Net loss	(11,362,364)	$ 0	0	(11,362,364)
Balance at Jun. 30, 2015	$ 9,053,807	$ 24,341	$ 38,138,754	$ (29,109,288)
Balance (in shares) at Jun. 30, 2015		24,338,219

Consolidated Statements of Sto6

Consolidated Statements of Stockholders' Equity (Parenthetical) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Common Stock
Payments of stock issuance costs	$ 3,144,479	$ 2,263,804

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (11,362,364)	$ (9,730,454)
Amortization of notes payable discount	0	3,356,000
Amortization of deferred financing costs	0	416,337
Amortization of intangible asset	5,255	3,544
Depreciation expense	128,870	7,759
Stock-based compensation expense	2,846,828	1,081,792
Stock issued for services	298,419	404,587
Warrant expense	93,564	126,427
Derivative losses	662,723	336,489
Bad debt expense	0	341,780
Forgiveness of accounts payable and accrued expenses - related party	(132,339)	0
Changes in operating assets and liabilities:
(Increase ) decrease in other assets	(49,868)	12,044
(Increase) decrease in inventory	222,382	(66,600)
Increase in due from related parties	0	18,947
Increase in accounts payable and accrued expenses	436,688	271,965
(Decrease) in accounts payable and accrued expenses - related party	(264,716)	(134,946)
Increase in interest payable	2,000	353,091
Deferred lease liability	33,664	33,881
Net Cash Used In Operating Activities	(7,078,894)	(3,167,357)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of fixed assets	(3,107,957)	(69,974)
Payment of deposit	0	(750,000)
Acquisition of intangibles	(55,000)	0
Increase in restricted cash	(450,167)	0
Decrease in interest receivable - related party	0	(10,211)
Net Cash Used In Investing Activities	(3,613,124)	(830,185)
CASH FLOWS FROM FINANCING ACTIVITIES:
Payments of financing costs	0	(270,300)
Proceeds from issuance of convertible notes payable	0	2,703,000
Repayments of convertible notes payable	0	(67,500)
Proceeds from issuance of notes payable - related party	0	234,700
Repayments of notes payable - related party	0	(234,700)
Payments on lease payable	(67,898)	0
Proceeds from issuance of equity financing	11,175,656	8,931,434
Payment of placement agent compensation and issuance costs	(1,071,568)	(1,365,085)
Net Cash Provided By Financing Activities	10,036,190	9,931,549
Net increase (decrease) in cash	(655,828)	5,934,007
Cash - Beginning of Year	5,934,534	527
Cash - End of Year	5,278,706	5,934,534
Cash Paid During the Period for:
Taxes	0	0
Interest	0	15,726
Non-Cash Transactions:
Conversion of convertible notes payable to common stock	0	6,308,000
Conversion of interest payable to common stock	0	722,587
Conversion of accounts payable and accrued expense - related party to common stock	0	275,000
Beneficial conversion feature recorded as a debt discount	0	2,922,938
Warrant value recorded as a debt discount	0	433,062
Warrant derivative liability reclassified as equity	2,342,039	1,407,739
Warrant value recorded as issuance costs	1,745,498	898,719
Accounts payable and Accrued expenses
Non-Cash Transactions:
Fixed assets acquired	511,400	0
Lease Payable
Non-Cash Transactions:
Fixed assets acquired	184,877	0
Tenant Improvements
Non-Cash Transactions:
Fixed assets acquired	$ 511,616	$ 0

Nature of Operations

Nature of Operations	12 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature Of Operation [Text Block]	Note 1 Nature of Operations These financial statements represent the consolidated financial statements of AntriaBio, Inc. (“AntriaBio”), formerly known as Fits My Style, Inc., and its wholly owned operating subsidiary, AntriaBio Delaware, Inc. (“Antria Delaware”). AntriaBio and Antria Delaware are collectively referred to herein as the “Company”. Effective May 1, 2014, the Company effected a 6 to 1 reverse split of the Company’s common stock, in which for every six (6) shares of common stock combined into one (1) share of common stock.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	Note 2 Summary of Significant Accounting Policies The principal accounting policies applied in the preparation of these financial statements are set out below. - The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). – These consolidated financial statements include the accounts of AntriaBio, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated. - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: the useful lives of depreciable assets, the fair value of share-based payments and warrants, fair value of derivative instruments, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates. - The Company's operations may be subject to significant risk and uncertainties including financial, operational, regulatory and other risks associated with a preclinical stage company, including the potential risk of business failure. See Note 3 regarding going concern matters. - In the statement of cash flows, cash includes cash in hand and other short-term highly liquid investments with original maturities of three months or less. The Company places its cash on deposit with financial institutions it believes to be of high quality. At times such cash investments may be in excess of the Federal Deposit Insurance Corporation (FDIC) insurance limits. – Restricted cash consists of cash held in a joint account with our general contractor until the completion of the construction in progress. – Inventory is stated at the lower of cost or market. Inventory consists of inventory purchased to make new material. All inventory is recorded at its acquisition cost. Fixed Assets – 2,315,803 23,012 . – Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The value of the current intangible asset is based on the asset values assigned in the asset acquisition discussed in Note 5. The intangible assets are being amortized over 11 7,292 – Deposits represent amounts paid as a security deposit on the lease of the facilities and is recorded at cost. Borrowings are recognized initially at the principal amount received. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized as interest expense in the statements of operation over the period of the borrowings using the effective interest method. The Company records a beneficial conversion feature (“BCF”) related to the issuance of a convertible note when issued. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. The value of the BCF is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense. - Research and development costs are expensed as incurred and include salaries, benefits and other staff-related costs; consultants and outside costs; material manufacturing costs; and facilities and other related costs. These costs relate to research and development costs without an allocation of general and administrative expenses. Expenses necessary to generate revenue are expensed in the period incurred. – The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the statements of operations. The Company adopted ASC 740 (formerly known as FIN No. 48, Accounting for Uncertainty in Income Taxes An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer and the board of directors that makes strategic decisions. The Company operates one segment. Comprehensive income (loss) is defined as all changes in stockholders’ equity from transactions and other events and circumstances. Therefore, comprehensive income (loss) includes our net loss and all charges and credits made directly to stockholders’ equity other than stockholders’ contributions and distributions. As of June 30, 2015 and 2014, the Company has no items other than net loss affecting comprehensive income (loss). Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted earnings per share is calculated on the treasury stock method, by dividing income available to common shareholders, adjusted for the effects of dilutive convertible securities, by the weighted average number of shares of common shares outstanding during the period and all additional common shares that would have been outstanding had all potential dilutive common shares been issued. 21,556,142 12,420,943 - From inception, the Company adopted ASC 820, Fair Value Measurements and Disclosures ⋅ Level 1: Quoted prices for identical assets and liabilities in active markets; ⋅ Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and ⋅ Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts of financial instruments including cash, restricted cash, accounts payable, and convertible notes payable approximated fair value as of June 30, 2015 and 2014 due to the relatively short maturity of the respective instruments. The warrant derivative liability recorded as of June 30, 2015 and 2014 is recorded at an estimated fair value based on a Black-Scholes pricing model. The warrant derivative liability recorded in the current period was recorded at an estimated fair value when recorded using an income approach based on a Lattice Model due to a down round provision. The warrant derivative liability is a level 3 fair value instrument with the entire change in the balance recorded through earnings. See significant assumptions in Note 10. Balance as of June 30, 2014 $ (35,595) Total unrealized gains (losses): Included in earnings (662,723) Warrant recorded as derivative liability (1,675,498) Warrant reclassified to equity 2,342,039 Balance as of June 30, 2015 $ (31,777) - In June 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-10, Development Stage Entities (Topic 915) In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern In January 2015, the FASB issued ASU 2015-01, Income Statement – Extraordinary and Unusual Items (Subtopic 225-20) – Certain amounts reported in prior years in the Consolidated Financial Statements have been reclassified to conform to the current year’s presentation. – The Company has considered subsequent events through the date of issuance of this Report on Form 10-K, and has determined no additional disclosure is necessary, other than those disclosed in the footnotes.

Going Concern

Going Concern	12 Months Ended
	Jun. 30, 2015
Going Concern [Abstract]
Going Concern Disclosure [Text Block]	Note 3 Going Concern As reflected in the accompanying financial statements, the Company has a net loss of $ 11,362,364 7,078,894 9,053,807 29,109,288 The Company expects that its current cash resources as well as expected lack of operating cash flows will not be sufficient to sustain operations for a period greater than one year. The ability of the Company to continue its operations is dependent on Management's plans, which include continuing to raise equity based financing. There is no assurance that the Company will be successful in accomplishing this objective. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Critical Accounting Estimates a

Critical Accounting Estimates and Judgments	12 Months Ended
	Jun. 30, 2015
Critical Accounting Estimates And Judgments [Abstract]
Critical Accounting Estimates And Judgments [Text Block]	Note 4 Critical Accounting Estimates and Judgments Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. The Company makes estimates and assumptions concerning the future. The resulting accounting estimates will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year include: Useful Life of Depreciable Assets – The Company is required to exercise judgment in determining the estimated useful life of depreciable assets. The useful life is determined based on management’s judgement. The useful lives are reviewed on a regular basis to determine that the useful life is consistent with current economic events and historical events. Share-based Payments and Warrants – The Company is required to exercise judgment in calculating the fair value of share based payments and warrants. The fair value calculation includes several inputs that are subject to management’s judgement. Management reviews these inputs on a regular basis to determine that the values used in the calculation are consistent with current economic events and historical events. Warrant Derivative Liability – The Company is required to exercise judgment in calculating the fair value of the warrant derivative liability. The fair value calculation includes several inputs that are subject to management’s judgement. Management reviews these inputs on a regular basis to determine that the values used in the calculation are consistent with current economic events and historical events. Contingent Liabilities - The Company is required to make judgments about contingent liabilities including the probability of pending and potential future litigation outcomes that, by their nature, are dependent on future events that are inherently uncertain. In making its determination of possible scenarios, management considers the evaluation of outside counsel knowledgeable about each matter, as well as known outcomes in case law. Income Taxes - Significant judgement is involved in determining the Company’s provision for income taxes, including any valuation allowance on deferred income tax assets. There are certain transactions and computations for which the ultimate tax determination is uncertain during the normal course of business. The Company recognizes liabilities for expected tax issues based upon estimates of whether additional taxes will be due. Where the final outcome of these matters is different from the amounts that were initially recognized, such difference will impact the income tax and deferred tax positions in the year in which such determination is made.

Acquisition of Assets

Acquisition of Assets	12 Months Ended
	Jun. 30, 2015
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	Note 5 Acquisition of Assets On January 30, 2013, the Company closed on an asset purchase agreement with the Chapter 7 Estate of PR Pharmaceuticals, Inc. (PRP). Pursuant to the agreement, the Company has acquired certain tangible and intangible assets in exchange for $ 400,000 100,000 44,000,000 On November 6, 2014, the Company closed on an asset purchase agreement with the Chapter 7 Estate of PRP in which the Company acquired its contingent consideration payments in exchange for $ 55,000

Fixed Assets

Fixed Assets	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	Note 6 Fixed Assets Useful Life June 30, 2015 June 30, 2014 Furniture and fixtures 5 - 7 years $ 55,330 $ 6,728 Lab equipment 3 - 15 years 889,672 315,951 Lab equipment (not yet placed in service) 3 - 15 years 1,371,441 - Leasehold Improvements 3 - 7 years 29,296 - Construction in process - 2,315,803 23,012 4,661,542 345,691 Less: accumulated depreciation and amortization (136,629) (7,759) $ 4,524,913 $ 337,932 Depreciation expense was $ 128,870 7,759

Related Party Transactions

Related Party Transactions	12 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Note 7 Related Party Transactions Effective September 1, 2011, the Company issued a $ 1,000,000 177,382 During the year ended June 30, 2015, the Company incurred consulting expenses of $ 99,000 132,339 During the year ended June 30, 2014, the Company incurred consulting expenses of $ 321,205 57,345 As of June 30, 2015 and 2014, the due from related party was zero for expenses paid on behalf of related parties. On March 31, 2014, $ 164,398

Convertible Notes Payable

Convertible Notes Payable	12 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Debt Disclosure [Text Block]	Note 8 Convertible Notes Payable From 2010 to 2012, the Company issued several series of convertible promissory notes for which principal and interest were due between six months and two years after issuance. The convertible notes allowed investors to convert their shares into common stock at the time of certain qualifying events with some of the notes also issuing warrants at the time of conversion. During 2014, the Company sent letters to the holders of the 2010, 2011 and 2012 notes requesting amendment of their convertible notes payable. The convertible notes payable were amended to: (i) fix the conversion price of the notes into common stock at $1.50 per share, (ii) require mandatory conversion convertible notes payable were amended to: (i) fix the conversion price of the notes into common stock at $ 1.50 3,032,500 653,000 653,000 2013 Notes – 8 3 1.26 1.26 1.89 The value of the proceeds of the notes was allocated to the warrants as discussed in Note 9 and the remaining balance was allocated to the beneficial conversion feature as the intrinsic value of the beneficial conversion feature is greater than the remaining value of the notes. The discount on the notes is being amortized into interest expense over the remaining life of the notes. On March 31, 2014, the Company closed on an equity transaction which qualified as a “qualified financing.” As such the $ 2,703,000 2,186,838 3,111,126 As of June 30, 2015 and 2014, the convertible notes outstanding balance was $ 60,000 60,000 8 Note Payable – Related Party – On November 14, 2013, the Company issued a 14 250,000 3 39,117 7.50 234,700 12,895 76,062

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit)	12 Months Ended
	Jun. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	Note 9 Shareholders’ Equity (Deficit) Common Stock - The Company is authorized to issue 200,000,000 0.001 a. One non-cumulative vote for each share held of record on all matters submitted to a vote of the stockholders; b. To participate equally and to receive any and all such dividends as may be declared by the Board of Directors out of funds legally available therefore; and c. To participate pro rata in any distribution of assets available for distribution upon liquidation. Stockholders have no pre-emptive rights to acquire additional shares of common stock or any other securities. Common shares are not subject to redemption and carry no subscription or conversion rights. Preferred Stock – The Company is authorized to issue 20,000,000 0.001 During 2014, the Company completed a private placement transaction in which the Company issued 5,725,327 2.34 36 7.6 1,365,085 898,719 In addition to the units issued, the Company also issued 562,352 For each dollar that was invested in the 2013 Notes, the Company would issue one-half of one common share purchase warrant for their investment in the private placement transaction for up to 150% of their investment in the 2013 Notes. 2.34 On March 26, 2014, the Company entered into a repayment agreement with a related party to issue 176,283 275,000 On March 31, 2014, the Company entered into a services agreement whereby the Company receives assistance with investor relations relating to digital strategy, website and investor materials, market awareness and other services. The compensation for these services will be 500,000 125,001 404,587 166,668 296,669 During 2015, the Company completed two private placement transactions in which the Company issued 6,040,921 2.50 10.1 1,071,568 2,072,911 37,838 70,000 The Company issued no shares of preferred stock during the years ended June 30, 2015 and 2014. The Company has not declared or paid any dividends or returned any capital to shareholders as of June 30, 2015 and 2014.

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Share Based Compensation [Text Block]	Note 10 Stock-Based Compensation Options - 1,500,000 4.50 819,445 541,667 138,888 8,334 4.50 On March 26, 2014, the Company adopted the AntriaBio, Inc. 2014 Stock and Incentive Plan which allows the Company to issue up to 3,750,000 2,835,000 1.29 3.44 On February 23, 2015, the Company adopted the AntriaBio, Inc. 2015 Non Qualified Stock Option Plan which allows the Company to issue up to 6,850,000 4,112,000 1.50 2.06 4 AntriaBio has computed the fair value of all options granted using the Black-Scholes option pricing model. In order to calculate the fair value of the options, certain assumptions are made regarding components of the model, including the estimated fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to valuation. AntriaBio estimated a volatility factor utilizing a comparable published volatility of a peer company. Due to the small number of option holders and all options being to officers, directors, or high level employees AntriaBio has estimated a forfeiture rate of zero. AntriaBio estimates the expected term based on the average of the vesting term and the contractual term of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. Expected volatility 90 - 103 % Risk free interest rate 1.31% - 2.38 % Expected term (years) 5 - 7 Dividend yield 0 % Weighted Weighted Average Number of Average Remaining Options Exercise Price Contractual Life Outstanding, June 30, 2013 1,508,334 $ 4.50 4.6 Granted 2,835,000 $ 3.14 Outstanding, June 30, 2014 4,343,334 $ 3.61 5.6 Granted 4,572,000 $ 2.02 Forfeited (212,916) $ 3.57 Outstanding, June 30, 2015 8,702,418 $ 2.78 7.1 Exercisable at June 30, 2015 2,539,751 $ 3.72 4.6 Stock-based compensation expense related to the fair value of stock options was included in the statement of operations as research and development - compensation and benefits expense of $ 671,958 2,174,870 1,081,792 11,465,433 Warrants - Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding, June 30, 2013 293,092 $ 2.21 4.1 Warrants issued to note holders 225,259 $ 1.89 Warrants issued to note holders 4,039,184 $ 1.98 Warrants issued to related party 39,117 $ 7.50 Warrants issued in private placement 6,287,679 $ 2.34 Warrants issued to placement agent 290,861 $ 1.56 Warrants issued for investor relations 66,667 $ 3.44 Warrants exercised (100,550) $ 1.17 Warrants forfeited (41,570) $ 1.17 Outstanding, June 30, 2014 11,099,739 $ 2.21 3.6 Warrants issued in private placements 6,040,921 $ 2.50 Warrants issued to placement agent 1,824,489 $ 2.50 Warrants issued for investor relations 111,000 $ 1.63 Warrants cancelled (59,758) $ 2.92 Outstanding, June 30, 2015 19,016,391 $ 2.33 3.0 Year Ended June 30, 2013: The Company issued warrants to purchase 41,424 2.03 233,334 2.03 1,000,000 18,334 4.95 Year Ended June 30, 2014: 225,259 1.89 39,117 7.50 4,039,184 1.98 6,287,679 2.34 2017 2014 290,861 1.56 66,667 3.44 Year Ended June 30, 2015: 6,040,921 2.50 1,824,489 2.50 105,000 1.65 6,000 1.38 The warrants exercisable for the 41,424 41,424 102,917 233,334 614,635 The warrants for the 225,259 shares of common stock are accounted for under equity treatment and were recorded at the allocated fair value as of the date of issuance. The fair value of the warrants was $524,594 and the allocated fair value of $433,062 was recorded into additional paid-in capital and as a discount to the note payable balance. The unamortized discount was fully expensed into interest upon the conversion of the bridge notes in fiscal 2014. The warrants exercisable for the 6,287,679 14,432,123 3,184,222 4,039,184 11,111,739 2,065,708 39,117 76,062 290,861 290,861 898,719 290,861 690,187 The warrants exercisable for the 66,667 50,365 31,777 35,595 The warrants exercisable for the 4,968,482 3,527,816 2,597,932 1,072,439 1,009,433 595,184 105,000 80,677 The warrants exercisable for the 1,477,287 58,914 92,111 1,418,373 1,498,809 2,217,605 347,202 247,552 309,121 99,650 172,809 124,434 On May 2, 2014, an investor elected to exercise their warrant under a net issue exercise in which 100,550 41,570 These warrants were valued using the Black-Scholes option pricing model on the date of issuance except for the warrants to purchase 290,861 1,518,387 The Black-Scholes valuation methodology was used because that model embodies all of the relevant assumptions that address the features underlying these instruments. Expected volatility 89% - 97 % Risk free interest rate 0.56% - 2.21 % Warrant term (years) 2 - 7 Dividend yield 0 % We utilize a Lattice model to determine the fair market value of the warrants to purchase 290,861 898,719 Expected volatility 93 % Risk free interest rate 2.21 % Warrant term (years) 7 Dividend yield 0 % We utilize a Lattice model to determine the fair market value of the warrants to purchase 1,418,373 1,498,809 Expected volatility 90% - 91 % Risk free interest rate 1.89% - 1.98 % Warrant term (years) 7 Dividend yield 0 % We utilize a Lattice model to determine the fair market value of the warrants to purchase 99,650 172,809 Expected volatility 90 % Risk free interest rate 1.71 % Warrant term (years) 7 Dividend yield 0 %

Income Taxes

Income Taxes	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	Note 11 Income Taxes Year Ended June 30, 2015 2014 Current tax benefit Federal $ - $ - State - - - - Deferred tax benefit Federal 3,774,110 2,006,831 State 432,092 79,548 Change in valuation allowance (4,206,202) (2,086,379) - - Total tax expense $ - $ - As of June 30, 2015 2014 Deferred tax assets Net operating loss carryforward $ 5,170,221 $ 2,267,379 Start-up and organizational expenses 181,154 457,495 Stock-based compensation 3,080,604 1,683,247 Derivative expense 12,275 129,986 Other 317,150 17,093 Total deferred tax assets 8,761,404 4,555,200 Valuation allowance (8,761,404) (4,555,200) Net deferred taxes $ - $ - The valuation allowance was established because the Company had not reported earnings in order to support the recognition of the deferred tax asset. The Company has net operating loss carryforwards of approximately $ 13,265,000 2031 6,281,000 34 Year Ended June 30, 2015 2014 Computed "expected" tax expense (benefit) $ (3,863,260) $ (3,308,354) Change in income taxes from: State taxes net of federal benefit (432,091) (79,549) Permanent differences 229,208 1,301,524 Prior period adjustment (140,059) - Change in valuation allowance 4,206,202 2,086,379 $ - $ -

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	Note 12 Commitments and Contingencies Lease Commitments – 27,000 28,939 3 34,381 750,000 Year Ending June 30, 2016 359,468 2017 370,252 2018 381,360 2019 392,855 2020 335,747 $ 1,839,682 In September 2014, the Company entered into an equipment lease for laboratory equipment to be leased for twenty-four months with a bargain purchase option at the end of the lease. The equipment lease has been recorded as a capital lease with monthly payments of $ 8,075 Year Ending June 30, 2016 $ 96,890 2017 24,223 Total rental commitments 121,113 Less: Interest payments (4,124) Total lease payable 116,989 Lease payable, current portion 93,852 Lease payable, less current portion $ 23,137 Legal Matters - From time to time, the Company may be involved in litigation relating to claims arising out of operations in the normal course of business. As of June 30, 2015, there were no pending or threatened lawsuits that could reasonably be expected to have a material effect on the results of our operations. There are no proceedings in which any of our directors, officers or affiliates, or any registered or beneficial shareholders, is an adverse party or has a material interest adverse to our interest.

Summary of Significant Accoun20

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Basis Of Accounting, Policy [Policy Text Block]	Basis of Presentation - The financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Consolidation, Policy [Policy Text Block]	Principals of Consolidation – These consolidated financial statements include the accounts of AntriaBio, Inc. and its wholly owned subsidiary. All material intercompany transactions and balances have been eliminated.
Use Of Estimates, Policy [Policy Text Block]	Accounting Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts in the financial statements and the accompanying notes. Such estimates and assumptions impact, among others, the following: the useful lives of depreciable assets, the fair value of share-based payments and warrants, fair value of derivative instruments, estimates of the probability and potential magnitude of contingent liabilities and the valuation allowance for deferred tax assets due to continuing and expected future operating losses. Actual results could differ from those estimates.
Risks and Uncertainties [Policy Text Block]	Risks and Uncertainties - The Company's operations may be subject to significant risk and uncertainties including financial, operational, regulatory and other risks associated with a preclinical stage company, including the potential risk of business failure. See Note 3 regarding going concern matters.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash - In the statement of cash flows, cash includes cash in hand and other short-term highly liquid investments with original maturities of three months or less. The Company places its cash on deposit with financial institutions it believes to be of high quality. At times such cash investments may be in excess of the Federal Deposit Insurance Corporation (FDIC) insurance limits.
Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash – Restricted cash consists of cash held in a joint account with our general contractor until the completion of the construction in progress.
Inventory, Policy [Policy Text Block]	Inventory – Inventory is stated at the lower of cost or market. Inventory consists of inventory purchased to make new material. All inventory is recorded at its acquisition cost.
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets – 2,315,803 23,012 .
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets – Costs of establishing patents, consisting of legal and filing fees paid to third parties, are expensed as incurred. The value of the current intangible asset is based on the asset values assigned in the asset acquisition discussed in Note 5. The intangible assets are being amortized over 11 7,292
Security Deposit [Policy Text Block]	Deposits – Deposits represent amounts paid as a security deposit on the lease of the facilities and is recorded at cost.
Convertible Notes Payable [Policy Text Block]	Convertible Notes Payable - Borrowings are recognized initially at the principal amount received. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized as interest expense in the statements of operation over the period of the borrowings using the effective interest method. The Company records a beneficial conversion feature (“BCF”) related to the issuance of a convertible note when issued. Beneficial conversion features that are contingent upon the occurrence of a future event are recorded when the contingency is resolved. The value of the BCF is recorded in the financial statements as a debt discount (premium) from the face amount of the note and such discount is amortized over the expected term of the convertible note (or to the conversion date of the note, if sooner) and is charged to interest expense.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Costs - Research and development costs are expensed as incurred and include salaries, benefits and other staff-related costs; consultants and outside costs; material manufacturing costs; and facilities and other related costs. These costs relate to research and development costs without an allocation of general and administrative expenses.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	General and Administrative Expenses - Expenses necessary to generate revenue are expensed in the period incurred.
Income Tax, Policy [Policy Text Block]	Income Taxes – The Company accounts for income taxes under an asset and liability approach. This process involves calculating the temporary and permanent differences between the carrying amounts of the assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The temporary differences result in deferred tax assets and liabilities, which would be recorded on the Company’s balance sheets in accordance with ASC 740, which established financial accounting and reporting standards for the effect of income taxes. The Company must assess the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent the Company believes that recovery is not likely, the Company must establish a valuation allowance. Changes in the Company’s valuation allowance in a period are recorded through the income tax provision on the statements of operations. The Company adopted ASC 740 (formerly known as FIN No. 48, Accounting for Uncertainty in Income Taxes An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Segment Reporting, Policy [Policy Text Block]	Segment Reporting – Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer and the board of directors that makes strategic decisions. The Company operates one segment.
Comprehensive Income, Policy [Policy Text Block]	Comprehensive Income (Loss) – Comprehensive income (loss) is defined as all changes in stockholders’ equity from transactions and other events and circumstances. Therefore, comprehensive income (loss) includes our net loss and all charges and credits made directly to stockholders’ equity other than stockholders’ contributions and distributions. As of June 30, 2015 and 2014, the Company has no items other than net loss affecting comprehensive income (loss).
Earnings Per Share, Policy [Policy Text Block]	Income (Loss) Per Common Share – Basic income (loss) per common share is calculated by dividing the net income (loss) available to the common shareholders by the weighted average number of common shares outstanding during that period. Diluted earnings per share is calculated on the treasury stock method, by dividing income available to common shareholders, adjusted for the effects of dilutive convertible securities, by the weighted average number of shares of common shares outstanding during the period and all additional common shares that would have been outstanding had all potential dilutive common shares been issued. Although there were common stock equivalents of 21,556,142 12,420,943
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments - From inception, the Company adopted ASC 820, Fair Value Measurements and Disclosures ⋅ Level 1: Quoted prices for identical assets and liabilities in active markets; ⋅ Level 2: Quoted prices for similar assets and liabilities in active markets; quoted prices for identical or similar assets and liabilities in markets that are not active; and model-derived valuations in which all significant inputs and significant value drivers are observable in active markets; and ⋅ Level 3: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable. The carrying amounts of financial instruments including cash, restricted cash, accounts payable, and convertible notes payable approximated fair value as of June 30, 2015 and 2014 due to the relatively short maturity of the respective instruments. The warrant derivative liability recorded as of June 30, 2015 and 2014 is recorded at an estimated fair value based on a Black-Scholes pricing model. The warrant derivative liability recorded in the current period was recorded at an estimated fair value when recorded using an income approach based on a Lattice Model due to a down round provision. The warrant derivative liability is a level 3 fair value instrument with the entire change in the balance recorded through earnings. See significant assumptions in Note 10. Balance as of June 30, 2014 $ (35,595) Total unrealized gains (losses): Included in earnings (662,723) Warrant recorded as derivative liability (1,675,498) Warrant reclassified to equity 2,342,039 Balance as of June 30, 2015 $ (31,777)
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Issued Accounting Pronouncements - In June 2014, the FASB issued Accounting Standards Update (“ASU”) 2014-10, Development Stage Entities (Topic 915) In August 2014, the FASB issued ASU 2014-15, Disclosure of Uncertainties About an Entity's Ability to Continue as a Going Concern In January 2015, the FASB issued ASU 2015-01, Income Statement – Extraordinary and Unusual Items (Subtopic 225-20)
Reclassification, Policy [Policy Text Block]	Reclassifications – Certain amounts reported in prior years in the Consolidated Financial Statements have been reclassified to conform to the current year’s presentation.
Subsequent Events, Policy [Policy Text Block]	Subsequent Events – The Company has considered subsequent events through the date of issuance of this Report on Form 10-K, and has determined no additional disclosure is necessary, other than those disclosed in the footnotes.

Summary of Significant Accoun21

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Fair Value, Instruments Classified in Shareholders Equity Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table sets forth a reconciliation of changes in the fair value of financial instruments classified as level 3 in the fair value hierarchy: Balance as of June 30, 2014 $ (35,595) Total unrealized gains (losses): Included in earnings (662,723) Warrant recorded as derivative liability (1,675,498) Warrant reclassified to equity 2,342,039 Balance as of June 30, 2015 $ (31,777)

Fixed Assets (Tables)

Fixed Assets (Tables)	12 Months Ended
	Jun. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	The following is a summary of fixed assets and accumulated depreciation: Useful Life June 30, 2015 June 30, 2014 Furniture and fixtures 5 - 7 years $ 55,330 $ 6,728 Lab equipment 3 - 15 years 889,672 315,951 Lab equipment (not yet placed in service) 3 - 15 years 1,371,441 - Leasehold Improvements 3 - 7 years 29,296 - Construction in process - 2,315,803 23,012 4,661,542 345,691 Less: accumulated depreciation and amortization (136,629) (7,759) $ 4,524,913 $ 337,932

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	AntriaBio has computed the fair value of all options granted during the year ended June 30, 2015 using the following assumptions: Expected volatility 90 - 103 % Risk free interest rate 1.31% - 2.38 % Expected term (years) 5 - 7 Dividend yield 0 %
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	Stock option activity is as follows: Weighted Weighted Average Number of Average Remaining Options Exercise Price Contractual Life Outstanding, June 30, 2013 1,508,334 $ 4.50 4.6 Granted 2,835,000 $ 3.14 Outstanding, June 30, 2014 4,343,334 $ 3.61 5.6 Granted 4,572,000 $ 2.02 Forfeited (212,916) $ 3.57 Outstanding, June 30, 2015 8,702,418 $ 2.78 7.1 Exercisable at June 30, 2015 2,539,751 $ 3.72 4.6
Schedule Of Warrants Issued To Agents Activity [Table Text Block]	AntriaBio issued warrants to agents in conjunction with the closing of various financings and issued warrants in note conversions and private placements as follows: Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding, June 30, 2013 293,092 $ 2.21 4.1 Warrants issued to note holders 225,259 $ 1.89 Warrants issued to note holders 4,039,184 $ 1.98 Warrants issued to related party 39,117 $ 7.50 Warrants issued in private placement 6,287,679 $ 2.34 Warrants issued to placement agent 290,861 $ 1.56 Warrants issued for investor relations 66,667 $ 3.44 Warrants exercised (100,550) $ 1.17 Warrants forfeited (41,570) $ 1.17 Outstanding, June 30, 2014 11,099,739 $ 2.21 3.6 Warrants issued in private placements 6,040,921 $ 2.50 Warrants issued to placement agent 1,824,489 $ 2.50 Warrants issued for investor relations 111,000 $ 1.63 Warrants cancelled (59,758) $ 2.92 Outstanding, June 30, 2015 19,016,391 $ 2.33 3.0
Black Scholes Pricing Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	Significant assumptions were as follows: Expected volatility 89% - 97 % Risk free interest rate 0.56% - 2.21 % Warrant term (years) 2 - 7 Dividend yield 0 %
Lattice Model
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	The estimated fair value was derived using the lattice model with the following assumptions: Expected volatility 93 % Risk free interest rate 2.21 % Warrant term (years) 7 Dividend yield 0 %
Lattice Model One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	The estimated fair value was derived using the lattice model with the following assumptions: Expected volatility 90% - 91 % Risk free interest rate 1.89% - 1.98 % Warrant term (years) 7 Dividend yield 0 %
Lattice Model Two
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share Based Payment Award Stock Warrants Valuation Assumptions [Table Text Block]	The estimated fair value was derived using the lattice model with the following assumptions: Expected volatility 90 % Risk free interest rate 1.71 % Warrant term (years) 7 Dividend yield 0 %

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Taxing jurisdictions related to income taxes are the Unites States Federal Government, the State of Colorado and the State of California. The provision for income taxes is as follows: Year Ended June 30, 2015 2014 Current tax benefit Federal $ - $ - State - - - - Deferred tax benefit Federal 3,774,110 2,006,831 State 432,092 79,548 Change in valuation allowance (4,206,202) (2,086,379) - - Total tax expense $ - $ -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	Deferred taxes are a result of differences between income tax accounting and GAAP with respect to income and expenses. The following is a summary of the components of deferred taxes recognized in the financial statements as of June 30, 2015 and 2014: As of June 30, 2015 2014 Deferred tax assets Net operating loss carryforward $ 5,170,221 $ 2,267,379 Start-up and organizational expenses 181,154 457,495 Stock-based compensation 3,080,604 1,683,247 Derivative expense 12,275 129,986 Other 317,150 17,093 Total deferred tax assets 8,761,404 4,555,200 Valuation allowance (8,761,404) (4,555,200) Net deferred taxes $ - $ -
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The income tax provision differs from the amount of income tax determined by applying the U.S. federal income tax rate of 34 Year Ended June 30, 2015 2014 Computed "expected" tax expense (benefit) $ (3,863,260) $ (3,308,354) Change in income taxes from: State taxes net of federal benefit (432,091) (79,549) Permanent differences 229,208 1,301,524 Prior period adjustment (140,059) - Change in valuation allowance 4,206,202 2,086,379 $ - $ -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Year Ending June 30, 2016 359,468 2017 370,252 2018 381,360 2019 392,855 2020 335,747 $ 1,839,682
Schedule of Future Minimum Lease Payments for Capital Leases [Table Text Block]	As of June 30, 2015, minimum rental commitment under the leases is as follows: Year Ending June 30, 2016 $ 96,890 2017 24,223 Total rental commitments 121,113 Less: Interest payments (4,124) Total lease payable 116,989 Lease payable, current portion 93,852 Lease payable, less current portion $ 23,137

Nature of Operations (Details T

Nature of Operations (Details Textual)	12 Months Ended
	Jun. 30, 2015
Stockholders' Equity, Reverse Stock Split	Effective May 1, 2014, the Company effected a 6 to 1 reverse split of the Company’s common stock, in which for every six (6) shares of common stock combined into one (1) share of common stock.

Summary of Significant Accoun27

Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2015USD ($)
Summary of Significant Accounting Policies [Line Items]
Balance as of June 30, 2014	$ (35,595)
Total unrealized gains (losses):
Included in earnings	(662,723)
Warrant recorded as derivative liability	(1,675,498)
Warrant reclassified to equity	2,342,039
Balance as of June 30, 2015	$ (31,777)

Summary of Significant Accoun28

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment, Gross	$ 4,661,542	$ 345,691
Income Tax Examination, Likelihood of Unfavorable Settlement	An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained.
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	$ 7,292
Finite-Lived Intangible Assets, Amortization Expense, Year Two	7,292
Finite-Lived Intangible Assets, Amortization Expense, Year Three	7,292
Finite-Lived Intangible Assets, Amortization Expense, Year Four	7,292
Finite-Lived Intangible Assets, Amortization Expense, Year Five	7,292
Construction in Process [Member]
Property, Plant and Equipment, Gross	$ 2,315,803	$ 23,012
Employee Stock Option [Member]
Weighted Average Number of Shares Outstanding, Diluted	21,556,142	12,420,943
Patents [Member]
Finite-Lived Intangible Asset, Useful Life	11 years

Going Concern (Details Textual)

Going Concern (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Net Loss	$ (11,362,364)	$ (9,730,454)
Net Cash Used In Operating Activities	(7,078,894)	(3,167,357)
Total Stockholders' Equity	9,053,807	6,406,731	$ (4,162,212)
Deficit accumulated during the development stage	$ (29,109,288)	$ (17,746,924)

Acquisition of Assets (Details

Acquisition of Assets (Details Textual) - USD ($)	Nov. 06, 2014	Jan. 30, 2013
Business Acquisition [Line Items]
Payments to Acquire Businesses, Gross		$ 400,000
Business Acquisition Purchases Price Allocation Assets Acquired		100,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset	$ 55,000
Maximum [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability, Current		$ 44,000,000

Fixed Assets (Details)

Fixed Assets (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Property, Plant and Equipment, Gross	$ 4,661,542	$ 345,691
Less: accumulated depreciation and amortization	(136,629)	(7,759)
Property, Plant and Equipment, Net	4,524,912	337,932
Furniture and Fixtures [Member]
Property, Plant and Equipment, Gross	$ 55,330	6,728
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years
Equipment [Member]
Property, Plant and Equipment, Gross	$ 889,672	315,951
Equipment [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Equipment [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	15 years
Equipment 1 [Member]
Property, Plant and Equipment, Gross	$ 1,371,441	0
Equipment 1 [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Equipment 1 [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	15 years
Leasehold Improvements [Member]
Property, Plant and Equipment, Gross	$ 29,296	0
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment, Useful Life	7 years
Construction in Progress [Member]
Property, Plant and Equipment, Gross	$ 2,315,803	$ 23,012

Fixed Assets (Details Textual)

Fixed Assets (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Depreciation	$ 128,870	$ 7,759

Related Party Transactions (Det

Related Party Transactions (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Sep. 30, 2011	Jun. 30, 2015	Jun. 30, 2014	Mar. 31, 2014
Consulting expenses		$ 99,000	$ 321,205
Professional fees		526,257	724,385
Forgiveness of accounts payable and accrued expenses - related party		(132,339)	0
Line Of Credit Issued To Related Party	$ 1,000,000
Due from Related Parties		$ 0	0	$ 164,398
Accounts Payable and Accrued Liabilities [Member]
Related party expenses			397,055
Accrued interest
Allowance for Loan and Lease Losses, Write-offs			177,382
Related Parties
Professional fees			$ 57,345

Convertible Notes Payable (Deta

Convertible Notes Payable (Details Textual) - USD ($)	Nov. 14, 2013	Mar. 31, 2014	Mar. 26, 2014	Jun. 30, 2015	Jun. 30, 2014	Jan. 31, 2014	Dec. 31, 2013
Debt instrument, convertible, conversion price					$ 1.50
Beneficial conversion feature recorded as a debt discount				$ 0	$ 2,922,938
Amortization of Debt Discount (Premium)				0	3,356,000
Interest Paid				0	15,726
Fair Value Of Warrants				$ 31,777	$ 35,595
Convertible Notes Payable
Debt instrument, interest rate, stated percentage				8.00%
Debt instrument, convertible, conversion price					$ 1.50
Debt conversion, converted instrument, amount					$ 3,032,500
Beneficial conversion feature recorded as a debt discount					$ 653,000
Debt instrument convertible number of common stock					3,111,126
Amortization of Debt Discount (Premium)					$ 653,000
Debt Instrument, Face Amount				$ 60,000	60,000
Convertible Notes Payable | Related Party
Qualified offering common stock	$ 3,000,000
Debt instrument, interest rate, stated percentage	14.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 7.50
Line of Credit Facility, Current Borrowing Capacity	$ 250,000
Warrants To Options Issued Upon Purchase Of Common Stock	39,117
Notes Payable, Related Parties, Current					234,700
Interest Paid					12,895
Fair Value Of Warrants			$ 76,062
2013 Notes
Qualified financing		$ 2,703,000
Debt instrument, interest rate, stated percentage							8.00%
Marketable securities, equity securities, current, total							$ 3,000,000
Common stock convertible conversion price							$ 1.26
Investment option convertible conversion price							1.26
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 1.89
Debt instrument convertible number of common stock		2,186,838
Convertible Notes Payable						$ 2,703,000	$ 2,703,000
2010 Notes
Debt conversion, converted instrument, amount					1.50
2011 Notes
Debt conversion, converted instrument, amount					1.50
2012 Notes
Debt conversion, converted instrument, amount					$ 1.50

Shareholders' Equity (Deficit)

Shareholders' Equity (Deficit) (Details Textual) - USD ($)	1 Months Ended			12 Months Ended
	May. 16, 2014	Mar. 31, 2014	Mar. 26, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2013
Stock issued during period, shares, new issues				166,668
Additional Warrants Issued				562,352
Adjustments to Additional Paid in Capital, Warrant Issued	$ 690,187			$ 6,026,070	$ 690,187
Common Stock, Shares Authorized				200,000,000	200,000,000
Common Stock, Par Or Stated Value Per Share				$ 0.001	$ 0.001
Preferred Stock, Shares Authorized				20,000,000	20,000,000
Preferred Stock, Par Or Stated Value Per Share				$ 0.001	$ 0.001
Accounts Payable and Accrued Liabilities [Member]
Stock Issued During Period, Shares, Other			176,283
Stock Issued During Period, Value, Other			$ 275,000
Compensation For Services [Member]
Stock Issued During Period, Shares, Other		500,000
Warrant
Adjustments to Additional Paid in Capital, Warrant Issued				$ 2,072,911	$ 898,719
Investor Relations
Stock Issued During Period, Shares, Other				166,668	125,001
Stock Issued During Period, Value, Other				$ 296,669	$ 404,587
2013 Notes
Class of Warrant or Right, Exercise Price of Warrants or Rights						$ 1.89
Private Placement
Stock issued during period, shares, new issues				6,040,921	5,725,327
Sale of stock, price per share					$ 2.34
Proceeds from issuance of private placement				$ 10,100,000	$ 7,600,000
Payments of stock issuance costs				$ 1,071,568	$ 1,365,085
Class of warrant or right of warrants or rights expiring period					36 months
Share Price				$ 2.50
Stock Issued During Period, Shares, Issued for Services				37,838
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs				$ 70,000
Private Placement | 2013 Notes
Description on additional warrants issuance to investors				For each dollar that was invested in the 2013 Notes, the Company would issue one-half of one common share purchase warrant for their investment in the private placement transaction for up to 150% of their investment in the 2013 Notes.
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 2.34

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)	12 Months Ended
	Jun. 30, 2015
Dividend yield	0.00%
Minimum
Expected volatility	90.00%
Risk free interest rate	1.31%
Expected term (years)	5 years
Maximum
Expected volatility	103.00%
Risk free interest rate	2.38%
Expected term (years)	7 years

Stock-Based Compensation (Det37

Stock-Based Compensation (Details 1) - Stock Option - $ / shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Number of Options
Outstanding	4,343,334	1,508,334
Granted	4,572,000	2,835,000
Forfeited	(212,916)
Outstanding	8,702,418	4,343,334	1,508,334
Exercisable	2,539,751
Weighted Average Exercise Price
Outstanding	$ 3.61	$ 4.50
Granted	2.02	3.14
Forfeited	3.57
Outstanding	2.78	$ 3.61	$ 4.50
Exercisable	$ 3.72
Weighted Average Remaining Contractual Life
Outstanding	7 years 1 month 6 days	5 years 7 months 6 days	4 years 7 months 6 days
Exercisable	4 years 7 months 6 days

Stock-Based Compensation (Det38

Stock-Based Compensation (Details 2) - Warrant - $ / shares	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Number of Warrants - Outstanding	11,099,739	293,092
Number of Warrants - Warrants issued to note holders		225,259
Number of Warrants - Warrants issued to note holders		4,039,184
Number of Warrants - Warrants issued to related party		39,117
Number of Warrants - Warrants issued in private placement	6,040,921	6,287,679
Number of Warrants - Warrants issued to placement agent	1,824,489	290,861
Number of Warrants - Warrants issued for investor relations	111,000	66,667
Number of Warrants - Warrants exercised		(100,550)
Number of Warrants - Warrants forfeited		(41,570)
Number of Warrants - Warrants cancelled	(59,758)
Number of Warrants - Outstanding	19,016,391	11,099,739	293,092
Weighted Average Exercise Price - Outstanding	$ 2.21	$ 2.21
Weighted Average Exercise Price - Warrants issued to note holders		1.89
Weighted Average Exercise Price - Warrants issued to note holders		1.98
Weighted Average Exercise Price - Warrants issued to related party		7.50
Weighted Average Exercise Price - Warrants issued in private placement	2.50	2.34
Weighted Average Exercise Price - Warrants issued to placement agent	2.50	1.56
Weighted Average Exercise Price - Warrants issued for investor relations	1.63	3.44
Weighted Average Exercise Price - Warrants exercised		1.17
Weighted Average Exercise Price - Warrants forfeited		1.17
Weighted Average Exercise Price - Warrants cancelled	2.92
Weighted Average Exercise Price - Outstanding	$ 2.33	$ 2.21	$ 2.21
Weighted Average Remaining Contractual Life - Outstanding	3 years	3 years 7 months 6 days	4 years 1 month 6 days

Stock-Based Compensation (Det39

Stock-Based Compensation (Details 3)	12 Months Ended
	Jun. 30, 2015
Dividend yield	0.00%
Black Scholes Pricing Model
Dividend yield	0.00%
Maximum
Expected volatility	103.00%
Risk free interest rate	2.38%
Warrant term (years)	7 years
Maximum | Black Scholes Pricing Model
Expected volatility	97.00%
Risk free interest rate	2.21%
Warrant term (years)	7 years
Minimum
Expected volatility	90.00%
Risk free interest rate	1.31%
Warrant term (years)	5 years
Minimum | Black Scholes Pricing Model
Expected volatility	89.00%
Risk free interest rate	0.56%
Warrant term (years)	2 years

Stock-Based Compensation (Det40

Stock-Based Compensation (Details 4)	12 Months Ended
	Jun. 30, 2015
Dividend yield	0.00%
Lattice Model | Warrant
Expected volatility	93.00%
Risk free interest rate	2.21%
Warrant term (years)	7 years
Dividend yield	0.00%

Stock-Based Compensation (Det41

Stock-Based Compensation (Details 5)	12 Months Ended
	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	103.00%
Risk free interest rate	2.38%
Warrant term (years)	7 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	90.00%
Risk free interest rate	1.31%
Warrant term (years)	5 years
Lattice Model One
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrant term (years)	7 years
Lattice Model One | Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Lattice Model One | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	91.00%
Risk free interest rate	1.98%
Lattice Model One | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	90.00%
Risk free interest rate	1.89%

Stock-Based Compensation (Det42

Stock-Based Compensation (Details 6)	12 Months Ended
	Jun. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Lattice Model Two | Warrant
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	90.00%
Risk free interest rate	1.71%
Warrant term (years)	7 years
Dividend yield	0.00%

Stock-Based Compensation (Det43

Stock-Based Compensation (Details Textual) - USD ($)	May. 02, 2014	Feb. 23, 2015	May. 16, 2014	Mar. 26, 2014	May. 31, 2013	Jan. 31, 2013	Jun. 30, 2015	Jun. 30, 2014	Apr. 06, 2015	Mar. 31, 2015	Apr. 01, 2014	Mar. 31, 2014	Jun. 30, 2013
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares					138,888
Stock-based compensation							$ 2,846,828	$ 1,081,792
Employee service share-based compensation, nonvested awards, total compensation cost not yet recognized, stock options							$ 11,465,433
Class of warrant or right, number of securities called by warrants or rights							105,000
Fair value of warrants							$ 31,777	35,595
Class of warrant exercisable warrants or rights							6,000				41,424
Adjustments to Additional Paid in Capital, Warrant Issued			$ 690,187				$ 6,026,070	690,187
Maximum Convertible Notes Payable Issuance													$ 1,000,000
Black Scholes Pricing Model
Class of warrant or right, number of securities called by warrants or rights		58,914
Adjustments to Additional Paid in Capital, Warrant Issued		$ 92,111
Lattice Model
Class of warrant or right, number of securities called by warrants or rights			290,861								290,861
Warrants to purchase common stock value							$ 172,809		$ 309,121
Warrant derivative liability											$ 898,719
Lattice Model One
Class of warrant or right, number of securities called by warrants or rights							1,418,373
Warrant derivative liability							$ 1,498,809
Lattice Model Two
Class of warrant or right, number of securities called by warrants or rights										99,650
Warrant derivative liability										$ 172,809
2014 Stock and Incentive Plan
Share-based compensation arrangement by share-based payment award, number of shares authorized				3,750,000
Two Consultants
Share-based compensation arrangement by share-based payment award, options, grants in period, gross							8,334
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price							$ 4.50
Employees and Directors | General and Administrative Expense [Member]
Stock-based compensation							$ 671,958	$ 0
Employees and Directors | 2014 Stock and Incentive Plan
Share-based compensation arrangement by share-based payment award, options, grants in period, gross				8,334			460,000	2,835,000
Share based compensation arrangement by share based payment award options shares purchased vested monthly term				4 years
Employees and Directors | 2014 Stock and Incentive Plan | Maximum
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price				$ 3.44
Employees and Directors | 2014 Stock and Incentive Plan | Minimum
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price		$ 1.50		$ 1.29
Employee Stock Option
Share-based compensation arrangement by share-based payment award, options, grants in period, gross							4,572,000	2,835,000
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price							$ 2.02	$ 3.14
Employee Stock Option | Research and Development Expense [Member]
Stock-based compensation							$ 2,174,870	$ 1,081,792
Employee Stock Option | Maximum
Share based compensation arrangement by share based payment award options shares purchased vested immediately						819,445
Share based compensation arrangement by share based payment award options shares purchased vested monthly						541,667
Employee Stock Option | Employees and Directors
Share-based compensation arrangement by share-based payment award, options, grants in period, gross						1,500,000	4,112,000
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price						$ 4.50
Share based compensation arrangement by share based payment award options shares purchased vested monthly term		4 years		0 years
Share-based compensation arrangement by share-based payment award, number of shares authorized		6,850,000
Employee Stock Option | Employees and Directors | Maximum
Share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price		$ 2.06
Additional Paid-in Capital and Professional Fee
Warrants to purchase common stock value							$ 80,677
Warrant
Class of warrant or right, number of securities called by warrants or rights							99,650
Fair value of class of warrants							$ 433,062
Fair value of warrants							$ 524,594
Class of warrant exercisable warrants or rights							225,259	18,334				233,334
Warrants to purchase common stock value								$ 191,126
Adjustments to Additional Paid in Capital, Warrant Issued							$ 2,072,911	$ 898,719
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period								41,570
Warrant | Black Scholes Pricing Model
Class of warrant or right, number of securities called by warrants or rights							290,861
Warrant | Lattice Model
Class of warrant or right, number of securities called by warrants or rights							1,518,387
Warrant | Investor
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised	100,550
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period	41,570
Warrant | Additional Paid-in Capital and Professional Fee
Warrants to purchase common stock value							$ 9,006
Warrant One
Class of warrant or right, number of securities called by warrants or rights							6,040,921	225,259					41,424
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 2.50	$ 1.89					$ 2.03
Class of warrant exercisable warrants or rights							41,424
Warrants to purchase common stock value							$ 102,917
Warrant Two
Class of warrant or right, number of securities called by warrants or rights							1,824,489						233,334
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 2.50						$ 2.03
Warrants to purchase common stock value												$ 614,635
Warrant Three
Class of warrant or right, number of securities called by warrants or rights							105,000						18,334
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 1.65						$ 4.95
Fair value of class of warrants							$ 3.44
Warrant Four
Class of warrant or right, number of securities called by warrants or rights							6,000
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 1.38
Warrant Five
Class of warrant or right, number of securities called by warrants or rights								39,117
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 7.50
Warrant Six
Class of warrant or right, number of securities called by warrants or rights								4,039,184
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 1.98
Warrant Seven
Class of warrant or right, number of securities called by warrants or rights								6,287,679
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 2.34
Warrant Eight
Class of warrant or right, number of securities called by warrants or rights								290,861
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 1.56
Warrant Nine
Class of warrant or right, number of securities called by warrants or rights								66,667
Class of Warrant or Right, Exercise Price of Warrants or Rights								$ 3.44
Warrant Ten
Class of warrant or right, number of securities called by warrants or rights							2,017
Fair value of warrants							$ 2,014
Fair value adjustment of warrants							$ 290,861
Warrant Eleven
Class of warrant or right, number of securities called by warrants or rights								6,287,679
Fair value of warrants								$ 14,432,123
Fair value adjustment of warrants								$ 3,184,222
Warrant Twelve
Class of warrant or right, number of securities called by warrants or rights								4,039,184
Fair value of warrants								$ 11,111,739
Fair value adjustment of warrants								$ 2,065,708
Warrant Thirteen
Class of warrant or right, number of securities called by warrants or rights								39,117
Fair value of warrants								$ 76,062
Warrant Fourteen
Class of warrant or right, number of securities called by warrants or rights								290,861
Warrant Fifteen
Class of warrant or right, number of securities called by warrants or rights							66,667
Adjustments to Additional Paid in Capital, Warrant Issued							$ 50,365
Warrant Fifteen | Lattice Model
Class of warrant or right, number of securities called by warrants or rights								290,861
Warrant derivative liability								$ 898,719
Warrant Sixteen
Class of warrant or right, number of securities called by warrants or rights							4,968,482
Warrants to purchase common stock value							$ 3,527,816
Adjustments to Additional Paid in Capital, Warrant Issued							$ 2,597,932
Warrant Seventeen
Class of warrant or right, number of securities called by warrants or rights							1,072,439
Fair value of class of warrants							$ 690,187
Fair value adjustment of warrants							$ 290,861
Class of warrant exercisable warrants or rights							1,477,287
Warrants to purchase common stock value							$ 1,009,433
Adjustments to Additional Paid in Capital, Warrant Issued							$ 595,184
Warrant Eighteen | Lattice Model
Class of warrant or right, number of securities called by warrants or rights							1,418,373
Warrant derivative liability							$ 1,498,809
Warrant Eighteen | Derivative Expense
Warrants to purchase common stock value		$ 2,217,605					$ 124,434
Warrant Ninteen
Class of warrant exercisable warrants or rights							347,202		247,552

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Current tax benefit
Federal	$ 0	$ 0
State	0	0
Current Income Tax Expense (Benefit)	0	0
Deferred tax benefit
Federal	3,774,110	2,006,831
State	432,092	79,548
Change in valuation allowance	(4,206,202)	(2,086,379)
Deferred Income Tax Expense (Benefit)	0	0
Total tax expense	$ 0	$ 0

Income Taxes (Details 1)

Income Taxes (Details 1) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
Deferred tax assets
Net operating loss carryforward	$ 5,170,221	$ 2,267,379
Start-up and organizational expenses	181,154	457,495
Stock-based compensation	3,080,604	1,683,247
Derivative expense	12,275	129,986
Other	317,150	17,093
Total deferred tax assets	8,761,404	4,555,200
Valuation allowance	(8,761,404)	(4,555,200)
Net deferred taxes	$ 0	$ 0

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($)	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Computed "expected" tax expense (benefit)	$ (3,863,260)	$ (3,308,354)
Change in income taxes from:
State taxes net of federal benefit	(432,091)	(79,549)
Permanent differences	229,208	1,301,524
Prior period adjustment	(140,059)	0
Change in valuation allowance	4,206,202	2,086,379
Income Tax Expense (Benefit)	$ 0	$ 0

Income Taxes (Details Textual)

Income Taxes (Details Textual)	12 Months Ended
	Jun. 30, 2015USD ($)
Operating Loss Carryforwards	$ 6,281,000
Operating Loss Carry forwards Expiration Year	2,031
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
Operating Loss Carryforwards, Valuation Allowance	$ 13,265,000

Commitments and Contingencies48

Commitments and Contingencies (Details)	Jun. 30, 2015USD ($)
Operating Leased Assets [Line Items]
2,016	$ 359,468
2,017	370,252
2,018	381,360
2,019	392,855
2,020	335,747
Operating Leases, Future Minimum Payments Due	$ 1,839,682

Commitments and Contingencies49

Commitments and Contingencies (Details 1) - USD ($)	Jun. 30, 2015	Jun. 30, 2014
2,016	$ 96,890
2,017	24,223
Total rental commitments	121,113
Less: Interest payments	(4,124)
Total lease payable	116,989
Lease payable, current portion	93,852	$ 0
Lease payable, less current portion	$ 23,127	$ 0

Commitments and Contingencies50

Commitments and Contingencies (Details Textual)	1 Months Ended
	May. 31, 2014USD ($)ft²	Jun. 30, 2015USD ($)	Sep. 30, 2014USD ($)
Operating Leases, Rent Expense	$ 28,939
Payments Of Monthly Lease Adjusted Annually Percentage	3.00%
Adjusted Triple Net Expense Of Lease Payments	$ 34,381
Area of Land | ft²	27,000
Security Deposit	$ 750,000
Capital Lease Obligations		$ 116,989
Capital Lease Obligations
Capital Lease Obligations			$ 8,075